PURE Bioscience (OTCMKTS:PURE) CEO Henry R. Lambert sold 41,500 shares of the stock in a transaction on Friday, January 12th. The shares were sold at an average price of $0.93, for a total value of $38,595.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
PURE Bioscience (OTCMKTS PURE) opened at $0.90 on Friday. PURE Bioscience has a 12 month low of $0.83 and a 12 month high of $1.36.
PURE Bioscience (OTCMKTS:PURE) last posted its quarterly earnings results on Thursday, December 14th. The company reported ($0.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.02). The company had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.65 million. PURE Bioscience had a negative net margin of 388.83% and a negative return on equity of 210.88%. equities analysts expect that PURE Bioscience will post -0.08 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “PURE Bioscience (PURE) CEO Sells $38,595.00 in Stock” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.themarketsdaily.com/2018/01/14/pure-bioscience-pure-ceo-sells-38595-00-in-stock.html.
About PURE Bioscience
PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.